Abbvie (ABBV) Stock Declined While Kcm Investment Advisors Has Cut Its Position by $343,758; Ingredion (INGR) Stock Value Declined While Indexiq Advisors Upped Stake by $1.43 Million

June 18, 2018 - By Linda Rogers

AbbVie Inc. (NYSE:ABBV) Logo

Indexiq Advisors Llc increased its stake in Ingredion Inc (INGR) by 401.08% based on its latest 2018Q1 regulatory filing with the SEC. Indexiq Advisors Llc bought 11,146 shares as the company’s stock declined 12.77% with the market. The institutional investor held 13,925 shares of the packaged foods company at the end of 2018Q1, valued at $1.80 million, up from 2,779 at the end of the previous reported quarter. Indexiq Advisors Llc who had been investing in Ingredion Inc for a number of months, seems to be bullish on the $8.30 billion market cap company. The stock increased 1.51% or $1.71 during the last trading session, reaching $114.84. About 746,946 shares traded or 52.97% up from the average. Ingredion Incorporated (NYSE:INGR) has declined 2.60% since June 18, 2017 and is downtrending. It has underperformed by 15.17% the S&P500. Some Historical INGR News: 23/04/2018 – Ingredion Presenting at Bank of Montreal Conference May 17; 03/05/2018 – Ingredion 1Q EPS $1.68; 21/03/2018 INGREDION INCORPORATED DECLARES QUARTERLY DIVIDEND OF $0.60 PER SHARE; 20/04/2018 – Moody’s: Upgrade Reflects Ingredion’s Success at Shifting Product Mix Toward Larger Proportion of Specialty Food, Starch Ingredients; 03/05/2018 – Ingredion 1Q Adj EPS $1.88; 20/04/2018 – Moody’s Expecs Ingredion Will Remain One of the Top Producers of Starches and Sweeteners; 20/04/2018 – INGREDION RAISED TO Baa1 FROM Baa2 BY MOODY’S; 03/05/2018 – Ingredion Sees 2018 EPS $7.90-EPS $8.20; 03/05/2018 – INGREDION INC INGR.N SEES FY 2018 ADJUSTED SHR $7.90 TO $8.20; 03/05/2018 – INGREDION INC QTRLY REPORTED SHR $1.90

Kcm Investment Advisors Llc decreased its stake in Abbvie Inc (ABBV) by 2.4% based on its latest 2018Q1 regulatory filing with the SEC. Kcm Investment Advisors Llc sold 3,657 shares as the company’s stock declined 16.83% with the market. The institutional investor held 148,775 shares of the major pharmaceuticals company at the end of 2018Q1, valued at $14.08 million, down from 152,432 at the end of the previous reported quarter. Kcm Investment Advisors Llc who had been investing in Abbvie Inc for a number of months, seems to be less bullish one the $150.76B market cap company. The stock increased 0.83% or $0.82 during the last trading session, reaching $99.57. About 20.81 million shares traded or 126.42% up from the average. AbbVie Inc. (NYSE:ABBV) has risen 52.41% since June 18, 2017 and is uptrending. It has outperformed by 39.84% the S&P500. Some Historical ABBV News: 24/05/2018 – FMI,MRK IN COLLABORATION PACT FOR KEYTRUDA COMPANION DIAGNOSTIC; 07/03/2018 – INVENTIVA SA IVAA.PA – PARTNERSHIP WITH ABBVIE AND BOEHRINGER INGELHEIM IS ADVANCING ON SCHEDULE; 22/03/2018 – Moody’s: Results of AbbVie’s TRINITY Trial in Lung Cancer Are Credit Negative; 02/05/2018 – AbbVie Presenting at Bank of America Conference May 16; 10/04/2018 – BerGenBio Completes Recruitment Into First Stage of Phase Il NSCLC Trial With Selective AXL Inhibitor Bemcentinib Combined With KEYTRUDA┬«; 16/04/2018 – Dynavax Reports Interim Data for SD-101 in Combination With KEYTRUDA(R) (pembrolizumab) in Patients With Advanced Squamous Cell Carcinoma of the Head and Neck; 30/05/2018 – AbbVie: 75.7M Shrs Properly Tendered and Not Properly Withdrawn At or Below Purchase Price of $105/Shr; 09/04/2018 – Upadacitinib Meets All Primary and Ranked Secondary Endpoints Including Superiority Versus Adalimumab in Phase 3 Study in Rheumatoid Arthritis; 24/04/2018 – Shire, Takeda reach breakthrough in $64 bln deal talks; 25/04/2018 – ABBVIE SUBMITS BLA FOR PLAQUE PSORIASIS DRUG RISANKIZUMAB

Investors sentiment increased to 1.01 in Q1 2018. Its up 0.01, from 1 in 2017Q4. It increased, as 40 investors sold INGR shares while 145 reduced holdings. 47 funds opened positions while 139 raised stakes. 59.83 million shares or 0.22% less from 59.96 million shares in 2017Q4 were reported. Dean Invest Lc invested in 0.13% or 6,764 shares. King Wealth holds 4,725 shares. Pillar Pacific Cap Limited Co has invested 0.03% in Ingredion Incorporated (NYSE:INGR). Maryland-based Price T Rowe Associate Md has invested 0% in Ingredion Incorporated (NYSE:INGR). Westpac Banking has 0% invested in Ingredion Incorporated (NYSE:INGR) for 33,421 shares. Cadinha Company Limited Liability Company invested in 0.08% or 3,016 shares. State Of Alaska Department Of Revenue reported 9,724 shares. Eulav Asset reported 34,800 shares. Oakbrook Limited Co stated it has 0.03% of its portfolio in Ingredion Incorporated (NYSE:INGR). Chevy Chase Trust stated it has 0% of its portfolio in Ingredion Incorporated (NYSE:INGR). M&R Cap Mngmt owns 1,722 shares. Cibc World Markets holds 132,200 shares. Prudential Public Ltd Company invested in 312,322 shares. Cornerstone Advsrs Inc has 0% invested in Ingredion Incorporated (NYSE:INGR). 1,769 were reported by Linscomb & Williams.

Indexiq Advisors Llc, which manages about $1.21 billion and $3.11B US Long portfolio, decreased its stake in Kennedy (NYSE:KW) by 18,433 shares to 123,438 shares, valued at $2.15M in 2018Q1, according to the filing. It also reduced its holding in Sabra Health Care Reit Inc (NASDAQ:SBRA) by 25,745 shares in the quarter, leaving it with 170,362 shares, and cut its stake in Consol Energy Inc New.

Among 7 analysts covering Ingredion Inc (NYSE:INGR), 3 have Buy rating, 1 Sell and 3 Hold. Therefore 43% are positive. Ingredion Inc had 25 analyst reports since August 3, 2015 according to SRatingsIntel. As per Friday, May 4, the company rating was maintained by Credit Suisse. BMO Capital Markets maintained Ingredion Incorporated (NYSE:INGR) rating on Wednesday, August 2. BMO Capital Markets has “Hold” rating and $12500 target. The stock of Ingredion Incorporated (NYSE:INGR) has “Overweight” rating given on Wednesday, November 15 by Stephens. The company was maintained on Wednesday, September 27 by BMO Capital Markets. The rating was maintained by Credit Suisse with “Buy” on Thursday, November 2. The stock of Ingredion Incorporated (NYSE:INGR) earned “Hold” rating by Citigroup on Friday, May 4. The rating was maintained by Jefferies with “Buy” on Friday, October 27. The stock has “Buy” rating by Jefferies on Wednesday, December 16. On Monday, June 26 the stock rating was maintained by BMO Capital Markets with “Hold”. The firm has “Market Perform” rating given on Friday, October 30 by BMO Capital Markets.

Investors sentiment decreased to 0.7 in Q1 2018. Its down 0.10, from 0.8 in 2017Q4. It worsened, as 61 investors sold ABBV shares while 737 reduced holdings. 127 funds opened positions while 428 raised stakes. 1.06 billion shares or 0.67% less from 1.06 billion shares in 2017Q4 were reported. Lodestar Invest Counsel Llc Il has 25,756 shares for 0.28% of their portfolio. Macnealy Hoover Invest Mgmt has invested 1.84% of its portfolio in AbbVie Inc. (NYSE:ABBV). Howland Capital Mgmt Lc stated it has 37,724 shares. Franklin Street Nc, North Carolina-based fund reported 179,564 shares. Tennessee-based Summit Asset Mgmt Ltd Liability Corporation has invested 0.11% in AbbVie Inc. (NYSE:ABBV). Dixon Hubard Feinour & Brown Inc Va has invested 0.16% in AbbVie Inc. (NYSE:ABBV). 6,205 are held by Parsec Fincl Mgmt. 147,705 were reported by First Midwest Comml Bank Tru Division. Alexandria Capital Ltd Co accumulated 7,519 shares. Spirit Of America Mngmt Corp New York holds 0.06% in AbbVie Inc. (NYSE:ABBV) or 4,700 shares. Orleans Mngmt La holds 2.57% in AbbVie Inc. (NYSE:ABBV) or 37,032 shares. Tudor Invest Et Al, Connecticut-based fund reported 86,054 shares. Polaris Greystone Finance Grp Limited Liability holds 0.05% of its portfolio in AbbVie Inc. (NYSE:ABBV) for 6,143 shares. Gemmer Asset Ltd holds 0.13% or 4,043 shares. Ima Wealth Incorporated stated it has 15,147 shares or 0.64% of all its holdings.

Since December 18, 2017, it had 0 insider buys, and 9 insider sales for $25.06 million activity. The insider RICHMOND TIMOTHY J. sold 18,129 shares worth $2.15 million. Schumacher Laura J sold $2.95 million worth of AbbVie Inc. (NYSE:ABBV) on Wednesday, February 28. Another trade for 2,643 shares valued at $311,684 was made by SEVERINO MICHAEL on Wednesday, February 28. Another trade for 83,574 shares valued at $9.57M was sold by ALBAN CARLOS. $8.31 million worth of AbbVie Inc. (NYSE:ABBV) shares were sold by CHASE WILLIAM J. $976,084 worth of stock was sold by GONZALEZ RICHARD A on Wednesday, February 28.

More notable recent AbbVie Inc. (NYSE:ABBV) news were published by: Fool.com which released: “3 Reasons to Expect Smooth Sailing for AbbVie’s Mission-Critical Candidate” on June 10, 2018, also Fool.com with their article: “Big Pharma Stock Investors Beware: Another $250 Billion Patent Cliff Is Coming” published on June 17, 2018, Fool.com published: “Better Buy: AbbVie Inc. vs. GlaxoSmithKline plc” on June 15, 2018. More interesting news about AbbVie Inc. (NYSE:ABBV) were released by: Benzinga.com and their article: “Benzinga’s Bulls & Bears Of The Week: AbbVie, Lululemon, Netflix, Snap And More” published on June 03, 2018 as well as Fool.com‘s news article titled: “Humira’s Sales Will Decline — and It’s Fantastic News for AbbVie” with publication date: June 13, 2018.

Among 24 analysts covering Abbvie Inc (NYSE:ABBV), 9 have Buy rating, 3 Sell and 12 Hold. Therefore 38% are positive. Abbvie Inc had 96 analyst reports since July 21, 2015 according to SRatingsIntel. The company was maintained on Wednesday, October 11 by BMO Capital Markets. Jefferies maintained it with “Buy” rating and $10 target in Friday, September 15 report. The rating was maintained by UBS on Friday, October 23 with “Buy”. As per Friday, July 14, the company rating was maintained by Jefferies. The stock of AbbVie Inc. (NYSE:ABBV) has “Buy” rating given on Tuesday, April 10 by Piper Jaffray. The stock of AbbVie Inc. (NYSE:ABBV) has “Buy” rating given on Friday, January 26 by Cowen & Co. The firm has “Equal-Weight” rating by Barclays Capital given on Thursday, April 5. As per Tuesday, December 1, the company rating was downgraded by Barclays Capital. The firm earned “Buy” rating on Monday, July 17 by Jefferies. The rating was downgraded by BMO Capital Markets to “Market Perform” on Friday, June 10.

Analysts await AbbVie Inc. (NYSE:ABBV) to report earnings on July, 27. They expect $1.97 earnings per share, up 38.73% or $0.55 from last year’s $1.42 per share. ABBV’s profit will be $2.98 billion for 12.64 P/E if the $1.97 EPS becomes a reality. After $1.87 actual earnings per share reported by AbbVie Inc. for the previous quarter, Wall Street now forecasts 5.35% EPS growth.

Ingredion Incorporated (NYSE:INGR) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


Recent Market News

>